;PMID: 7985080 ;source_file_1414.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..31] = [t:0..31] ;1)sentence:[e:36..136] = [t:36..136] ;2)section:[e:140..198] = [t:140..198] ;3)section:[e:202..287] = [t:202..287] ;4)sentence:[e:291..302] = [t:291..302] ;5)sentence:[e:303..426] = [t:303..426] ;6)sentence:[e:427..544] = [t:427..544] ;7)sentence:[e:545..553] = [t:545..553] ;8)sentence:[e:554..669] = [t:554..669] ;9)sentence:[e:670..876] = [t:670..876] ;10)sentence:[e:877..995] = [t:877..995] ;11)sentence:[e:996..1004] = [t:996..1004] ;12)sentence:[e:1006..1223] = [t:1006..1223] ;13)sentence:[e:1224..1283] = [t:1224..1283] ;14)sentence:[e:1284..1415] = [t:1284..1415] ;15)sentence:[e:1416..1554] = [t:1416..1554] ;16)sentence:[e:1555..1737] = [t:1555..1737] ;17)sentence:[e:1738..1917] = [t:1738..1917] ;18)sentence:[e:1918..2120] = [t:1918..2120] ;19)sentence:[e:2121..2133] = [t:2121..2133] ;20)sentence:[e:2134..2257] = [t:2134..2257] ;21)section:[e:2261..2305] = [t:2261..2305] ;section 0 Span:0..31 ;Surgery 1994 Dec;116(6):1010-6 (SEC (FRAG (NNP:[0..7] Surgery) (CD:[9..13] 1994) (IN:[14..22] Dec;116-LRB-) (CD:[22..24] 6-RRB-) (CD:[24..29] :1010) (HYPH:[29..30] -) (CD:[30..31] 6))) ;sentence 1 Span:36..136 ;N-ras mutation: an independent prognostic factor for aggressiveness of ;papillary thyroid carcinoma. ;[36..41]:gene-rna:"N-ras" ;[107..135]:malignancy:"papillary thyroid carcinoma" (SENT (NP-HLN (NP (NN:[36..41] N-ras) (NN:[42..50] mutation)) (::[50..51] :) (NP (NP (DT:[52..54] an) (JJ:[55..66] independent) (JJ:[67..77] prognostic) (NN:[78..84] factor)) (PP (IN:[85..88] for) (NP (NP (NN:[89..103] aggressiveness)) (PP (IN:[104..106] of) (NP (JJ:[107..116] papillary) (NN:[118..125] thyroid) (NN:[126..135] carcinoma)))))) (.:[135..136] .))) ;section 2 Span:140..198 ;Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. (SEC (FRAG (NNP:[140..144] Hara) (NNP:[145..146] H) (,:[146..147] ,) (NNP:[148..154] Fulton) (NNP:[155..156] N) (VBD:[156..157] ,) (NNP:[158..165] Yashiro) (NNP:[166..167] T) (,:[167..168] ,) (NNP:[169..172] Ito) (NNP:[173..174] K) (,:[174..175] ,) (NNP:[176..183] DeGroot) (NNP:[184..186] LJ) (,:[186..187] ,) (NNP:[188..194] Kaplan) (NNP:[195..198] EL.))) ;section 3 Span:202..287 ;Department of Surgery, University of Chicago Pritzker School of Medicine, Ill ; 60637. (SEC (FRAG (NNP:[202..212] Department) (IN:[213..215] of) (NNP:[216..223] Surgery) (,:[223..224] ,) (NNP:[225..235] University) (IN:[236..238] of) (NNP:[239..246] Chicago) (NNP:[247..255] Pritzker) (NNP:[256..262] School) (IN:[263..265] of) (NNP:[266..274] Medicine) (,:[274..275] ,) (NNP:[276..279] Ill) (.:[281..286] 60637) (.:[286..287] .))) ;sentence 4 Span:291..302 ;BACKGROUND. (SENT (NP (NN:[291..301] BACKGROUND) (.:[301..302] .))) ;sentence 5 Span:303..426 ;The clinical importance of point mutations of ras oncogene in differentiated ;thyroid cancers has not been fully clarified. ;[330..345]:variation-type:"point mutations" ;[349..352]:gene-rna:"ras" ;[366..396]:malignancy:"differentiated thyroid cancers" (SENT (S (NP-SBJ-1 (NP (DT:[303..306] The) (JJ:[307..315] clinical) (NN:[316..326] importance)) (PP (IN:[327..329] of) (NP (NP (NN:[330..335] point) (NNS:[336..345] mutations)) (PP (IN:[346..348] of) (NP (NN:[349..352] ras) (NN:[353..361] oncogene))) (PP (IN:[362..364] in) (NP (VBN:[366..380] differentiated) (NN:[381..388] thyroid) (NNS:[389..396] cancers)))))) (VP (VBZ:[397..400] has) (RB:[401..404] not) (VP (VBN:[405..409] been) (ADVP (RB:[410..415] fully)) (VP (VBN:[416..425] clarified) (NP-1 (-NONE-:[425..425] *))))) (.:[425..426] .))) ;sentence 6 Span:427..544 ;The purpose of this study is to determine the prognostic importance of ras ;mutation in papillary thyroid carcinoma. ;[499..502]:gene-rna:"ras" ;[515..543]:malignancy:"papillary thyroid carcinoma" (SENT (S (NP-SBJ (NP (DT:[427..430] The) (NN:[431..438] purpose)) (PP (IN:[439..441] of) (NP (DT:[442..446] this) (NN:[448..453] study)))) (VP (VBZ:[454..456] is) (S-NOM-PRD (NP-SBJ (-NONE-:[456..456] *)) (VP (TO:[457..459] to) (VP (VB:[460..469] determine) (NP (NP (DT:[470..473] the) (JJ:[474..484] prognostic) (NN:[485..495] importance)) (PP (IN:[496..498] of) (NP (NN:[499..502] ras) (NN:[503..511] mutation)))) (PP (IN:[512..514] in) (NP (JJ:[515..524] papillary) (NN:[526..533] thyroid) (NN:[534..543] carcinoma))))))) (.:[543..544] .))) ;sentence 7 Span:545..553 ;METHODS. (SENT (NP (NNS:[545..552] METHODS) (.:[552..553] .))) ;sentence 8 Span:554..669 ;Tumors of 91 patients with papillary carcinoma were studied; mean follow-up ;was 14.1 years (range, 1 to 40 years). ;[581..600]:malignancy:"papillary carcinoma" (SENT (S (S (NP-SBJ-1 (NP (NNS:[554..560] Tumors)) (PP (IN:[561..563] of) (NP (NP (CD:[564..566] 91) (NNS:[567..575] patients)) (PP (IN:[576..580] with) (NP (JJ:[581..590] papillary) (NN:[591..600] carcinoma)))))) (VP (VBD:[601..605] were) (VP (VBN:[607..614] studied) (NP-1 (-NONE-:[614..614] *))))) (::[614..615] ;) (S (NP-SBJ (JJ:[616..620] mean) (VB:[621..627] follow) (HYPH:[627..628] -) (RP:[628..630] up)) (VP (VBD:[631..634] was) (NP-TMP-PRD (CD:[635..639] 14.1) (NNS:[640..645] years) (PRN (-LRB-:[646..647] -LRB-) (S (NP-SBJ (NN:[647..652] range)) (,:[652..653] ,) (NP-PRD (QP (CD:[654..655] 1) (TO:[656..658] to) (CD:[659..661] 40)) (NNS:[662..667] years))) (-RRB-:[667..668] -RRB-))))) (.:[668..669] .))) ;sentence 9 Span:670..876 ;Patients were grouped as follows: class I, intrathyroidal disease, n = 21; ;class II, cervical node metastases, n = 22; class III, extrathyroidal ;disease, n = 19; and class IV, distant metastases, n = 29. ;[714..736]:malignancy:"intrathyroidal disease" ;[756..781]:malignancy:"cervical node metastases" ;[802..824]:malignancy:"extrathyroidal disease" ;[849..867]:malignancy:"distant metastases" (SENT (S (NP-SBJ-1 (NNS:[670..678] Patients)) (VP (VBD:[679..683] were) (VP (VBN:[685..692] grouped) (NP-1 (-NONE-:[692..692] *)) (PP (IN:[693..695] as) (FRAG (VP (VBZ:[696..703] follows) (::[703..704] :)) (FRAG (FRAG (NP (NN:[705..710] class) (CD:[711..712] I)) (,:[712..713] ,) (NP (JJ:[714..728] intrathyroidal) (NN:[729..736] disease)) (,:[736..737] ,) (S (NP-SBJ (NN:[738..739] n)) (VP (SYM:[740..741] =) (NP (CD:[742..744] 21))))) (::[744..745] ;) (FRAG (NP (NN:[746..751] class) (CD:[752..754] II)) (,:[754..755] ,) (NP (JJ:[756..764] cervical) (NN:[766..770] node) (NNS:[771..781] metastases)) (,:[781..782] ,) (S (NP-SBJ (NN:[783..784] n)) (VP (SYM:[785..786] =) (NP (CD:[787..789] 22))))) (::[789..790] ;) (FRAG (NP (NN:[791..796] class) (CD:[797..800] III)) (,:[800..801] ,) (NP (JJ:[802..816] extrathyroidal) (NN:[817..824] disease)) (,:[824..825] ,) (S (NP-SBJ (NN:[826..827] n)) (VP (SYM:[828..829] =) (NP (CD:[830..832] 19))))) (::[832..833] ;) (CC:[834..837] and) (FRAG (NP (NN:[838..843] class) (CD:[845..847] IV)) (,:[847..848] ,) (NP (JJ:[849..856] distant) (NNS:[857..867] metastases)) (,:[867..868] ,) (S (NP-SBJ (NN:[869..870] n)) (VP (SYM:[871..872] =) (NP (CD:[873..875] 29)))))))))) (.:[875..876] .))) ;sentence 10 Span:877..995 ;DNA was analyzed with polymerase chain reaction, oligonucleotide ;hybridization, and DNA sequence analysis techniques. ;[899..909]:gene-protein:"polymerase" (SENT (S (NP-SBJ-1 (NN:[877..880] DNA)) (VP (VBD:[881..884] was) (VP (VBN:[885..893] analyzed) (NP-1 (-NONE-:[893..893] *)) (PP-MNR (IN:[894..898] with) (NP (NP (NN:[899..909] polymerase) (NN:[910..915] chain) (NN:[916..924] reaction)) (,:[924..925] ,) (NP (NN:[927..942] oligonucleotide) (NN:[943..956] hybridization)) (,:[956..957] ,) (CC:[958..961] and) (NP (NN:[962..965] DNA) (NN:[966..974] sequence) (NN:[975..983] analysis) (NNS:[984..994] techniques)))))) (.:[994..995] .))) ;sentence 11 Span:996..1004 ;RESULTS. (SENT (NP (NNS:[996..1003] RESULTS) (.:[1003..1004] .))) ;sentence 12 Span:1006..1223 ;Thirteen (14.3%) of 91 tumors showed an N-ras point mutation: 4.8% (1 of 21) ;patients in class I; 4.5% (1 of 22) patients in class II; 15.8% (3 of 19) ;patients in class III; and 27.8% (8 of 29) patients in class IV. ;[1029..1035]:malignancy:"tumors" ;[1046..1051]:gene-rna:"N-ras" ;[1052..1066]:variation-type:"point mutation" (SENT (S (NP-SBJ (NP (CD:[1006..1014] Thirteen) (PRN (-LRB-:[1015..1016] -LRB-) (NP (CD:[1016..1020] 14.3) (NN:[1020..1021] %)) (-RRB-:[1021..1022] -RRB-))) (PP (IN:[1023..1025] of) (NP (CD:[1026..1028] 91) (NNS:[1029..1035] tumors)))) (VP (VBD:[1036..1042] showed) (NP (DT:[1043..1045] an) (NN:[1046..1051] N-ras) (NN:[1052..1057] point) (NN:[1058..1066] mutation)) (::[1066..1067] :) (NP (NP (NP (CD:[1068..1071] 4.8) (NN:[1071..1072] %) (PRN (-LRB-:[1073..1074] -LRB-) (NP (NP (CD:[1074..1075] 1)) (PP (IN:[1076..1078] of) (NP (CD:[1079..1081] 21)))) (-RRB-:[1081..1082] -RRB-)) (NNS:[1084..1092] patients)) (PP (IN:[1093..1095] in) (NP (NN:[1096..1101] class) (CD:[1102..1103] I)))) (::[1103..1104] ;) (NP (NP (CD:[1105..1108] 4.5) (NN:[1108..1109] %) (PRN (-LRB-:[1110..1111] -LRB-) (NP (NP (CD:[1111..1112] 1)) (PP (IN:[1113..1115] of) (NP (CD:[1116..1118] 22)))) (-RRB-:[1118..1119] -RRB-)) (NNS:[1120..1128] patients)) (PP (IN:[1129..1131] in) (NP (NN:[1132..1137] class) (CD:[1138..1140] II)))) (::[1140..1141] ;) (NP (NP (CD:[1142..1146] 15.8) (NN:[1146..1147] %) (PRN (-LRB-:[1148..1149] -LRB-) (NP (NP (CD:[1149..1150] 3)) (PP (IN:[1151..1153] of) (NP (CD:[1154..1156] 19)))) (-RRB-:[1156..1157] -RRB-)) (NNS:[1159..1167] patients)) (PP (IN:[1168..1170] in) (NP (NN:[1171..1176] class) (CD:[1177..1180] III)))) (::[1180..1181] ;) (CC:[1182..1185] and) (NP (NP (CD:[1186..1190] 27.8) (NN:[1190..1191] %) (PRN (-LRB-:[1192..1193] -LRB-) (NP (NP (CD:[1193..1194] 8)) (PP (IN:[1195..1197] of) (NP (CD:[1198..1200] 29)))) (-RRB-:[1200..1201] -RRB-)) (NNS:[1202..1210] patients)) (PP (IN:[1211..1213] in) (NP (NN:[1214..1219] class) (CD:[1220..1222] IV)))))) (.:[1222..1223] .))) ;sentence 13 Span:1224..1283 ;Each mutation changed codon 61 from glutamine to arginine. ;[1229..1237]:variation-event:"mutation" ;[1247..1255]:variation-location:"codon 61" ;[1261..1270]:variation-state-original:"glutamine" ;[1274..1282]:variation-state-altered:"arginine" (SENT (S (NP-SBJ (DT:[1224..1228] Each) (NN:[1229..1237] mutation)) (VP (VBD:[1239..1246] changed) (NP (NN:[1247..1252] codon) (CD:[1253..1255] 61)) (PP (IN:[1256..1260] from) (NP (NN:[1261..1270] glutamine))) (PP (TO:[1271..1273] to) (NP (NN:[1274..1282] arginine)))) (.:[1282..1283] .))) ;sentence 14 Span:1284..1415 ;Patients with distant metastases (8 of 29) had a significantly higher ;incidence of ras mutations than others (5 of 62, p = 0.01). ;[1298..1316]:malignancy:"distant metastases" ;[1368..1371]:gene-rna:"ras" (SENT (S (NP-SBJ (NP (NNS:[1284..1292] Patients)) (PP (IN:[1293..1297] with) (NP (JJ:[1298..1305] distant) (NNS:[1306..1316] metastases))) (PRN (-LRB-:[1317..1318] -LRB-) (SBAR (CD:[1318..1319] 8)) (PP (IN:[1321..1323] of) (NP (CD:[1324..1326] 29))) (-RRB-:[1326..1327] -RRB-))) (VP (VBD:[1328..1331] had) (NP (NP (DT:[1332..1333] a) (ADJP (RB:[1334..1347] significantly) (JJR:[1348..1354] higher)) (NN:[1355..1364] incidence)) (PP (IN:[1365..1367] of) (NP (NN:[1368..1371] ras) (NNS:[1372..1381] mutations))) (PP (IN:[1382..1386] than) (NP (NNS:[1387..1393] others)))) (PRN (-LRB-:[1394..1395] -LRB-) (FRAG (NP (NP (CD:[1395..1396] 5)) (PP (IN:[1397..1399] of) (NP (CD:[1401..1403] 62)))) (,:[1403..1404] ,) (S (NP-SBJ (NN:[1405..1406] p)) (VP (SYM:[1407..1408] =) (NP (CD:[1409..1413] 0.01))))) (-RRB-:[1413..1414] -RRB-))) (.:[1414..1415] .))) ;sentence 15 Span:1416..1554 ;Patients in classes III and IV also had a higher incidence of mutations (11 ;of 48) than patients in classes I and II (2 of 43, p = 0.01). (SENT (S (NP-SBJ (NP (NNS:[1416..1424] Patients)) (PP (IN:[1425..1427] in) (NP (NP (NML-2 (NNS:[1428..1435] classes)) (CD:[1436..1439] III)) (CC:[1440..1443] and) (NP (NML-2 (-NONE-:[1443..1443] *P*)) (CD:[1444..1446] IV))))) (ADVP (RB:[1447..1451] also)) (VP (VBD:[1452..1455] had) (NP (NP (NP (DT:[1456..1457] a) (JJR:[1458..1464] higher) (NN:[1465..1474] incidence)) (PP (IN:[1475..1477] of) (NP (NNS:[1479..1488] mutations)))) (PRN (-LRB-:[1489..1490] -LRB-) (NP (NP (CD:[1490..1492] 11)) (PP (IN:[1493..1495] of) (NP (CD:[1496..1498] 48)))) (-RRB-:[1498..1499] -RRB-)) (PP (IN:[1500..1504] than) (NP (NP (NNS:[1505..1513] patients)) (PP (IN:[1514..1516] in) (NP (NP (NML-1 (NNS:[1517..1524] classes)) (CD:[1525..1526] I)) (CC:[1527..1530] and) (NP (NML-1 (-NONE-:[1530..1530] *P*)) (CD:[1531..1533] II))))))) (PRN (-LRB-:[1534..1535] -LRB-) (FRAG (NP (NP (CD:[1535..1536] 2)) (PP (IN:[1537..1539] of) (NP (CD:[1540..1542] 43)))) (,:[1542..1543] ,) (S (NP-SBJ (NN:[1544..1545] p)) (VP (SYM:[1546..1547] =) (NP (CD:[1548..1552] 0.01))))) (-RRB-:[1552..1553] -RRB-))) (.:[1553..1554] .))) ;sentence 16 Span:1555..1737 ;The incidence of ras mutations was significantly higher in patients who died ;of papillary cancer (5 of 15, 33.3%) than in patients who are still alive (8 ;of 76, 10.5%) (p = 0.02). ;[1573..1576]:gene-rna:"ras" ;[1637..1653]:malignancy:"papillary cancer" (SENT (S (NP-SBJ (NP (DT:[1555..1558] The) (NN:[1560..1569] incidence)) (PP (IN:[1570..1572] of) (NP (NN:[1573..1576] ras) (NNS:[1577..1586] mutations)))) (VP (VBD:[1587..1590] was) (ADJP-PRD (ADJP (RB:[1591..1604] significantly) (JJR:[1605..1611] higher)) (PP-3 (-NONE-:[1611..1611] *ICH*))) (PP (IN:[1612..1614] in) (NP (NP (NNS:[1615..1623] patients)) (SBAR (WHNP-2 (WP:[1624..1627] who)) (S (NP-SBJ-2 (-NONE-:[1627..1627] *T*)) (VP (VBD:[1628..1632] died) (PP (IN:[1633..1635] of) (NP (JJ:[1637..1646] papillary) (NN:[1647..1653] cancer)))))))) (PRN (-LRB-:[1654..1655] -LRB-) (FRAG (NP (NP (CD:[1655..1656] 5)) (PP (IN:[1657..1659] of) (NP (CD:[1660..1662] 15)))) (,:[1662..1663] ,) (NP (CD:[1664..1668] 33.3) (NN:[1668..1669] %))) (-RRB-:[1669..1670] -RRB-)) (PP-3 (IN:[1671..1675] than) (PP (IN:[1676..1678] in) (NP (NP (NNS:[1679..1687] patients)) (SBAR (WHNP-1 (WP:[1688..1691] who)) (S (NP-SBJ-1 (-NONE-:[1691..1691] *T*)) (VP (VBP:[1692..1695] are) (ADVP (RB:[1696..1701] still)) (ADJP-PRD (JJ:[1702..1707] alive)) (PRN (-LRB-:[1708..1709] -LRB-) (FRAG (NP (NP (CD:[1709..1710] 8)) (PP (IN:[1711..1713] of) (NP (CD:[1714..1716] 76)))) (,:[1716..1717] ,) (NP (CD:[1719..1723] 10.5) (NN:[1723..1724] %))) (-RRB-:[1724..1725] -RRB-)))))))) (PRN (-LRB-:[1726..1727] -LRB-) (S (NP-SBJ (NN:[1727..1728] p)) (VP (SYM:[1729..1730] =) (NP (CD:[1731..1735] 0.02)))) (-RRB-:[1735..1736] -RRB-))) (.:[1736..1737] .))) ;sentence 17 Span:1738..1917 ;Kaplan-Meier survival curves also showed a greater mortality from tumor (p < ;0.05) and a higher recurrence rate (p < 0.01) in ras-positive tumors than in ;the ras-negative group. ;[1805..1810]:malignancy:"tumor" ;[1865..1868]:gene-rna:"ras" ;[1879..1885]:malignancy:"tumors" ;[1898..1901]:gene-rna:"ras" (SENT (S (NP-SBJ (NML (NNP:[1738..1744] Kaplan) (HYPH:[1744..1745] -) (NNP:[1745..1750] Meier)) (NN:[1751..1759] survival) (NNS:[1760..1766] curves)) (ADVP (RB:[1767..1771] also)) (VP (VBD:[1772..1778] showed) (NP (NP (NP (NP (DT:[1779..1780] a) (JJR:[1781..1788] greater) (NN:[1789..1798] mortality)) (PP-1 (-NONE-:[1798..1798] *ICH*))) (PP (IN:[1800..1804] from) (NP (NN:[1805..1810] tumor))) (PRN (-LRB-:[1811..1812] -LRB-) (S (NP-SBJ (NN:[1812..1813] p)) (VP (SYM:[1814..1815] <) (NP (CD:[1816..1820] 0.05)))) (-RRB-:[1820..1821] -RRB-))) (CC:[1822..1825] and) (NP (NP (NP (DT:[1826..1827] a) (JJR:[1828..1834] higher) (NN:[1835..1845] recurrence) (NN:[1846..1850] rate)) (PP-1 (-NONE-:[1850..1850] *ICH*))) (PRN (-LRB-:[1851..1852] -LRB-) (S (NP-SBJ (NN:[1852..1853] p)) (VP (SYM:[1854..1855] <) (NP (CD:[1856..1860] 0.01)))) (-RRB-:[1860..1861] -RRB-)))) (PP-1 (IN:[1862..1864] in) (NP (ADJP (NN:[1865..1868] ras) (HYPH:[1868..1869] -) (JJ:[1869..1877] positive)) (NNS:[1879..1885] tumors)))) (PP (IN:[1886..1890] than) (PP (IN:[1891..1893] in) (NP (DT:[1894..1897] the) (ADJP (NN:[1898..1901] ras) (HYPH:[1901..1902] -) (JJ:[1902..1910] negative)) (NN:[1911..1916] group)))) (.:[1916..1917] .))) ;sentence 18 Span:1918..2120 ;Finally, in studies by multivariate analyses, positive ras mutation and age ;were shown to be two independent prognostic factors for prediction of death ;from papillary cancer and recurrence of cancer. ;[1974..1977]:gene-rna:"ras" ;[2077..2093]:malignancy:"papillary cancer" ;[2113..2119]:malignancy:"cancer" (SENT (S (ADVP (RB:[1918..1925] Finally)) (,:[1925..1926] ,) (PP (IN:[1927..1929] in) (NP (NP (NNS:[1930..1937] studies)) (PP (IN:[1938..1940] by) (NP (JJ:[1941..1953] multivariate) (NNS:[1955..1963] analyses))))) (,:[1963..1964] ,) (NP-SBJ-1 (NP (JJ:[1965..1973] positive) (NN:[1974..1977] ras) (NN:[1978..1986] mutation)) (CC:[1987..1990] and) (NP (NN:[1991..1994] age))) (VP (VBD:[1995..1999] were) (VP (VBN:[2000..2005] shown) (S (NP-SBJ-1 (-NONE-:[2005..2005] *)) (VP (TO:[2006..2008] to) (VP (VB:[2009..2011] be) (NP-PRD (NP (CD:[2012..2015] two) (JJ:[2016..2027] independent) (JJ:[2029..2039] prognostic) (NNS:[2040..2047] factors)) (PP (IN:[2048..2051] for) (NP (NP (NN:[2052..2062] prediction)) (PP (IN:[2063..2065] of) (NP (NP (NP (NN:[2066..2071] death)) (PP (IN:[2072..2076] from) (NP (JJ:[2077..2086] papillary) (NN:[2087..2093] cancer)))) (CC:[2094..2097] and) (NP (NP (NN:[2098..2108] recurrence)) (PP (IN:[2110..2112] of) (NP (NN:[2113..2119] cancer)))))))))))))) (.:[2119..2120] .))) ;sentence 19 Span:2121..2133 ;CONCLUSIONS. (SENT (NP (NNS:[2121..2132] CONCLUSIONS) (.:[2132..2133] .))) ;sentence 20 Span:2134..2257 ;Mutation of N-ras gene at codon 61 is an independent prognostic factor for ;aggressiveness of papillary thyroid carcinomas. ;[2134..2142]:variation-event:"Mutation" ;[2146..2151]:gene-rna:"N-ras" ;[2160..2168]:variation-location:"codon 61" ;[2228..2256]:malignancy:"papillary thyroid carcinomas" (SENT (S (NP-SBJ (NP (NN:[2134..2142] Mutation)) (PP (IN:[2143..2145] of) (NP (NN:[2146..2151] N-ras) (NN:[2152..2156] gene))) (PP (IN:[2157..2159] at) (NP (NN:[2160..2165] codon) (CD:[2166..2168] 61)))) (VP (VBZ:[2169..2171] is) (NP-PRD (NP (DT:[2172..2174] an) (JJ:[2175..2186] independent) (JJ:[2188..2198] prognostic) (NN:[2199..2205] factor)) (PP (IN:[2206..2209] for) (NP (NP (NN:[2210..2224] aggressiveness)) (PP (IN:[2225..2227] of) (NP (JJ:[2228..2237] papillary) (NN:[2238..2245] thyroid) (NNS:[2246..2256] carcinomas))))))) (.:[2256..2257] .))) ;section 21 Span:2261..2305 ;PMID: 7985080 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2261..2265] PMID) (::[2265..2266] :) (CD:[2267..2274] 7985080) (IN:[2275..2276] -LSB-) (NNP:[2276..2282] PubMed) (HYPH:[2283..2284] -) (JJ:[2285..2292] indexed) (IN:[2293..2296] for) (NNP:[2297..2305] MEDLINE-RSB-)))